sorafenib has been researched along with losartan potassium in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (losartan potassium) | Trials (losartan potassium) | Recent Studies (post-2010) (losartan potassium) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 24,390 | 2,493 | 5,408 |
| Protein | Taxonomy | sorafenib (IC50) | losartan potassium (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8.53 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0049 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.0082 | |
| Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, Y; Iizuka, J; Ishimori, I; Kennoki, T; Kimata, N; Kobayashi, H; Kondo, T; Murakami, J; Nakazawa, H; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Agarwal, KL; Bakris, GL; Bhatta, SS; Cohen, EE; Karrison, T; Maitland, ML; Ratain, MJ; Seiwert, TY; Sit, L; Vokes, EE; Wroblewski, KE | 1 |
2 other study(ies) available for sorafenib and losartan potassium
| Article | Year |
|---|---|
Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Erythropoietin; Feasibility Studies; Hematinics; Hemoglobins; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Sample Size; Sorafenib; Treatment Outcome | 2011 |
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Topics: Axitinib; Blood Pressure; Clinical Trials as Topic; Combined Modality Therapy; Erythrocyte Count; Erythropoiesis; Erythropoietin; Fluorouracil; Humans; Imidazoles; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |